NASDAQ:BWAY Brainsway (BWAY) Stock Price, News & Analysis $15.34 +0.08 (+0.52%) Closing price 04:00 PM EasternExtended Trading$15.31 -0.03 (-0.20%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Brainsway Stock (NASDAQ:BWAY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Brainsway alerts:Sign Up Key Stats Today's Range$14.70▼$15.4950-Day Range$10.91▼$15.9052-Week Range$7.06▼$16.00Volume114,921 shsAverage Volume55,991 shsMarket Capitalization$289.93 millionP/E Ratio59.00Dividend YieldN/APrice Target$18.00Consensus RatingBuy Company Overview BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel. Read More Brainsway Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreBWAY MarketRank™: Brainsway scored higher than 61% of companies evaluated by MarketBeat, and ranked 418th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingBrainsway has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBrainsway has only been the subject of 2 research reports in the past 90 days.Read more about Brainsway's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth100.00% Earnings GrowthEarnings for Brainsway are expected to grow by 100.00% in the coming year, from $0.08 to $0.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Brainsway is 58.85, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.67.Price to Earnings Ratio vs. SectorThe P/E ratio of Brainsway is 58.85, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.76.Price to Book Value per Share RatioBrainsway has a P/B Ratio of 4.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Brainsway's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.54% of the float of Brainsway has been sold short.Short Interest Ratio / Days to CoverBrainsway has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Brainsway has recently decreased by 25.27%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBrainsway does not currently pay a dividend.Dividend GrowthBrainsway does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.54% of the float of Brainsway has been sold short.Short Interest Ratio / Days to CoverBrainsway has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Brainsway has recently decreased by 25.27%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment0.30 News SentimentBrainsway has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Brainsway this week, compared to 2 articles on an average week.Search Interest2 people have searched for BWAY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Brainsway to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Brainsway insiders have not sold or bought any company stock.Percentage Held by Insiders19.00% of the stock of Brainsway is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.11% of the stock of Brainsway is held by institutions.Read more about Brainsway's insider trading history. Receive BWAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brainsway and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BWAY Stock News HeadlinesHC Wainwright Reaffirms "Buy" Rating for Brainsway (NASDAQ:BWAY)August 27 at 2:09 AM | americanbankingnews.comBrainsWay: Deep TMS Gains Traction, But Valuation Leaves Little Room For ErrorAugust 26 at 7:20 PM | seekingalpha.comWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.August 28 at 2:00 AM | SmartAsset (Ad)BrainsWay Falters on New InvestmentAugust 21, 2025 | baystreet.caBrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.August 21, 2025 | globenewswire.comBrainsWay Acquires Minority Stake in Axis Integrated Mental HealthAugust 21, 2025 | msn.comBrainsWay Acquires Minority-Stake in Axis Integrated Mental HealthAugust 20, 2025 | globenewswire.comQ3 Earnings Forecast for Brainsway Issued By Northland CapmkAugust 17, 2025 | americanbankingnews.comSee More Headlines BWAY Stock Analysis - Frequently Asked Questions How have BWAY shares performed this year? Brainsway's stock was trading at $9.43 on January 1st, 2025. Since then, BWAY shares have increased by 62.2% and is now trading at $15.30. How were Brainsway's earnings last quarter? Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) issued its quarterly earnings results on Wednesday, August, 13th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.07 by $0.03. The business earned $12.63 million during the quarter, compared to the consensus estimate of $12.34 million. Brainsway had a trailing twelve-month return on equity of 8.97% and a net margin of 11.60%. Read the conference call transcript. When did Brainsway IPO? Brainsway (BWAY) raised $30 million in an IPO on Wednesday, April 17th 2019. The company issued 2,500,000 shares at $11.94 per share. Cantor acted as the underwriter for the IPO. Who are Brainsway's major shareholders? Top institutional shareholders of Brainsway include Phoenix Financial Ltd. (1.92%), Acadian Asset Management LLC (1.77%), ARK Investment Management LLC (1.06%) and Huntleigh Advisors Inc. (0.41%). How do I buy shares of Brainsway? Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Brainsway own? Based on aggregate information from My MarketBeat watchlists, some other companies that Brainsway investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Novo Nordisk A/S (NVO) and AppLovin (APP). Company Calendar Last Earnings8/13/2025Today8/28/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:BWAY CIK1505065 Webwww.brainsway.com Phone(722) 582-4030FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Price Target for Brainsway$18.00 High Price Target$19.00 Low Price Target$17.00 Potential Upside/Downside+18.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)$0.26 Trailing P/E Ratio58.66 Forward P/E Ratio190.63 P/E GrowthN/ANet Income$2.92 million Net Margins11.60% Pretax Margin12.66% Return on Equity8.97% Return on Assets5.65% Debt Debt-to-Equity RatioN/A Current Ratio3.51 Quick Ratio3.34 Sales & Book Value Annual Sales$41.02 million Price / Sales7.03 Cash Flow$0.24 per share Price / Cash Flow63.76 Book Value$3.60 per share Price / Book4.24Miscellaneous Outstanding Shares18,900,000Free Float15,311,000Market Cap$288.23 million OptionableNot Optionable Beta1.42 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:BWAY) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainsway Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainsway With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.